AT007, an aldose reductase inhibitor, is currently commercialized as the orphan drug Govorestat by Applied Therapeutics; Govorestat has not yet advanced in clinical trial for PMM2-CDG but is currently in clinical trial for different diseases (galactosemia, NCT04902781, and SORD Deficiency, NCT05397665) [81]. This evidence concerns the gene AKR1B1 and galactosemia.